home / stock / ptix / ptix quote
Last: | $2.24 |
---|---|
Change Percent: | -39.62% |
Open: | $3.0877 |
Close: | $2.24 |
High: | $3.0877 |
Low: | $2.2 |
Volume: | 3,051,649 |
Last Trade Date Time: | 04/27/2021 04:55:58 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.24 | $3.0877 | $2.24 | $3.0877 | $2.2 | 3,051,649 | 04-27-2021 |
$3.71 | $4.15 | $3.71 | $4.15 | $3.71 | 1,114 | 04-26-2021 |
$4.9 | $4.9 | $4.9 | $4.9 | $4.9 | 551 | 04-21-2021 |
$4.82 | $5.2 | $4.82 | $5.2 | $4.82 | 367 | 04-19-2021 |
$5.2 | $6.25 | $5.2 | $6.25 | $5.2 | 2,396 | 04-15-2021 |
$6.5 | $6.5 | $6.5 | $6.75 | $6.5 | 1,672 | 04-13-2021 |
$6.5 | $6.5 | $6.5 | $6.5 | $6.5 | 2,202 | 04-12-2021 |
$5.82 | $5.82 | $5.82 | $5.82 | $5.82 | 128 | 03-31-2021 |
$6.25 | $6.05 | $6.25 | $6.25 | $6.05 | 200 | 03-23-2021 |
$5.8 | $5.8 | $5.8 | $5.8 | $5.8 | 276 | 03-22-2021 |
$5.7 | $5.7 | $5.7 | $5.7 | $5.7 | 120 | 03-11-2021 |
$6.25 | $6.25 | $6.25 | $6.25 | $6.25 | 136 | 03-08-2021 |
$6.51 | $6.51 | $6.51 | $6.51 | $6.51 | 310 | 03-04-2021 |
$7 | $6.5 | $7 | $7 | $6.5 | 401 | 03-02-2021 |
$5.65 | $5.65 | $5.65 | $5.65 | $5.65 | 415 | 02-26-2021 |
$5.5 | $6 | $5.5 | $6 | $5.5 | 749 | 02-19-2021 |
$5.6 | $5.6 | $5.6 | $5.6 | $5.6 | 211 | 02-18-2021 |
$4.15 | $4.16 | $4.15 | $4.16 | $4.15 | 405 | 02-15-2021 |
$4.15 | $4.16 | $4.15 | $4.16 | $4.15 | 405 | 02-12-2021 |
$4.14 | $4.14 | $4.14 | $4.14 | $4.14 | 242 | 02-02-2021 |
News, Short Squeeze, Breakout and More Instantly...
Protagenic Therapeutics Inc. Company Name:
PTIX Stock Symbol:
OTCMKTS Market:
Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneer in biopharmaceutical research, announced today that Dr. Andrew Slee, Chief Operating Officer, will present a tal...
Transitioned from Pre-Clinical to Clinical Stage company in FY 2023 Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized Anxiety Disorder, progressing through Phase 1 portion Plans to enroll final tw...
Next clinical progress update expected in April 2024 NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, advances its mission to develop cutting-edge treatments for stress-related neuropsychiatric disorders. The ...